TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Relational Commitment (RC)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Physiological Parameters Tracking Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of treatment with GLP-1 or GLP-1/GIP combination drug
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: VT recurrence free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Major peri-intubation adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Progression-free survival at 6 month
Endpoint domain: Mortality/survival
Primary endpoint: Average blood glucose management (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life: Patient Reported Outcomes Measurement Information System Global-10
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of TEAEs leading to study drug discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and characteristics of presumed infusion reactions
Endpoint domain: Adverse events/effects
Primary endpoint: AUROC of convolutional neural network in predicting vault after ICL surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUROC of convolutional neural network in predicting anterior chamber angle after ICL implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time spent in Active Play
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fundamental movement skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of the arcade of Struthers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice-Related Quality of Life (V-RQOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of PLS240 treated participants with a ≥30% decrease in mean iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of participants with a corrected serum calcium (cCa) <7.5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants with a corrected serum calcium (cCa) <8.3 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Confirmed Motor Progression Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythroid progenitor cells (EPCs) detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Treatment Responses of Index Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic recurrence of hallux valgus deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak change from baseline of heart rate (CFBmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak change from baseline of systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak change from baseline of diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak change from baseline of quantitative electrocardiogram PR interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Contour Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose/recommended phase II dose (MTD/RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HF event or CV death
Endpoint domain: Mortality/survival
Primary endpoint: Clinician Administered PTSD Scale for DSM-5 (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency, Intensity, Burden of Side Effects (FIBSER)
Endpoint domain: Adverse events/effects
Primary endpoint: Greene climacteric questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Daily hot flash diary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of recruited patients that consent
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of patients randomized to the interventional arm who complete the palliative care consult prior to tumor board
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Long COVID Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of Long COVID symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of care needs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in number of medication access problems
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with Vaginal Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: capillary density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of dilated capillaries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: detection of other abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in glycemic control measured by HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of altitude-related adverse health effects
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Tear Break-Up Time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes in Corneal & Conjunctival Fluorescein staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Delivery occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Characterize plasma pharmacokinetic (PK) parameters of REC-4881
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from baseline in polyp burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants in Each Risk Category
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of postpartum diabetes mellitus screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time from hospital arrival to angiography suite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with Adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with AE leading to discontinuation of GSK1070806
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with Serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with adverse event of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Cost effectiveness ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: amount of activity in the pallidothalamic pathway from stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relationship (slope) between the measures of bradykinesia and total pathway activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of epidural SCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selectivity of epidural SCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: toxicity of the combination of mirdametinib and vorinostat
Endpoint domain: Adverse events/effects
Primary endpoint: response of therapeutic targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: utility of radiographic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving serum potassium < 5.5mEq/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Expression levels of platelet surface markers of activation and aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Expression levels of platelet microRNAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Seminal fluid volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of adverse events during treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in King's Health Questionnaire (KHQ) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PROMIS® Global Health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PROMIS® 29+2 Profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 12-item WHODAS 2.0
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Vital Sign Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Electrocardiogram (ECG) Abnormalities specific to QTc elevation
Endpoint domain: Adverse events/effects
Primary endpoint: Six Spot Step Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CAT
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Corneal Epithelial Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eye Dryness Score (EDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of detecting OMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline PROMIS Global Health Scale at 6, 12, and 18 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma Area Under Concentration-time Curve from zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Area under the concentration-curve from zero to the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glottic visualization grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell Yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular Growth Kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cellular Phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate-to-Vigorous Physical Activity Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet Quality Summary Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of skin network (SRa parameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Assessment of skin network (SRq parameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Assessment of sebum metabolites' composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: comfort level in preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain and stress level in preterm infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient mortality rate after kidney transplant
Endpoint domain: Mortality/survival
Primary endpoint: Utilization of Carer eSupport
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Clinician Erythema Assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Montgomery-Åsberg Depression Rating Scale (MADRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: recurrence of ASBO
Endpoint domain: Mortality/survival
Primary endpoint: Functional level assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cumulative Protective Efficacy Against HPV-16 and/or HPV-18-Related Cervical Intraepithelial Neoplasia (CIN) Grade 2 or Higher (CIN2+), Adenocarcinoma In Situ (AIS), and Cervical Cancer
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with recurrence or dead after treatment and remission
Endpoint domain: Mortality/survival
Primary endpoint: Median time from remission to recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome of patients with severe pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Dose (RD)
Endpoint domain: Physiological/clinical
Primary endpoint: Coronary lesions assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to the time of last quantifiable analyte concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of abdominal aortic aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Severity of Body-Focused Repetitive Behaviors (BFRBs) as reported by parents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of Body-Focused Repetitive Behaviors (BFRBs) as self-reported by the child
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arthroscopic Visualization Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Foot Placement Error from baseline 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VOR Gain from baseline 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clinically relevant events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Zarit Caregiver Burden Interview (ZBI) total scores
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Change in Perceived Stress Scale-10 (PSS-10) total scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Short-Form Health Survey-12 (SF-12) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Unintentional missed treatment days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prostate specific antigen (PSA) nadir < 0.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum viscoelasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response to GnRH triggering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cycloplegic refraction change in spherical equivalent refraction (SER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency
Endpoint domain: Life impact
Primary endpoint: Early Rad51/DNA damage response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Late Rad51/DNA damage response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of mobile application delivered exercise program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Completion of standard exercise program
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area under the plasma concentration-time curve (AUC[0-T])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oocyte yield per retrieval or egg freezing cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mature oocytes cryopreserved per egg freezing cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: average IPSS change from baseline to 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from treatment-related adverse SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Adverse pregnancy outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of successfully treated bleeding episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With No Change or Reduction in Number of T1 Gd-Enhancing Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Blood loss as estimated by postoperative decreases in hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants Who Renew Medicaid Coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Anthropometric measurements (Weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical measurements (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of unexpected serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Short Mood and Feelings Questionnaire-Child (SMFQ-C)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Short Mood and Feelings Questionnaire-Adult (SMFQ-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PROMIS Anxiety - Child
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PROMIS Anxiety - Adult
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bladder pain intensity differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy based on Area Under Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Pain and Disability Index (SPADI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Range of Motion (Active and Pain-Free)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and AEs judged to be related to study medication
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Electrocardiogram (ECG) Abnormalities specific to QTc elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants with absence seizure freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Freedom from device-related SAE during the first 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Compression Force in Newtons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EMMA app use daily interactions
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Change in Daily Assessment of Independent Living and Executive Skills (DAILIES)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Cognitive Self-efficacy Questionnaire (CSEQ)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Patient-Reported Outcome Measurement Information System 29 general (PROMIS-29)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Alive status
Endpoint domain: Mortality/survival
Primary endpoint: Number of Serious Adverse Events Reported
Endpoint domain: Adverse events/effects
Primary endpoint: euploid blastocyst formation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Safety and tolerability of phage therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with one or more Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Predictive ability of morphology and/or movement of the tongue, hyoid bone and suprahyoid muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving for the main substance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of dose-limiting toxicities and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue